Get Started
HBV Curricula
Step 1




The Advanced Certificate Program in Chronic Hepatitis B Management VI:
Bridging Cultural Differences to Improve HBV Treatment in Asian
and Other Diverse Communities
  1. Curriculum VII
  2. Curriculum VI
  3. Curriculum V
  4. Curriculum IV
  5. Full Course List
Co-Chairs
faculty image
Adrian M. Di Bisceglie, MD, FACP
  • Badeeh A. & Catherine V. Bander
  •    Chair in Internal Medicine
  • Chairman and Professor of Internal Medicine
  • Chief of Hepatology
  • Saint Louis University
  •    School of Medicine
  • St. Louis, Missouri
    • faculty image
    Robert G. Gish, MD
  • Medical Director
  • Center for Hepatobiliary Disease and
  •    Abdominal Transplantation
  • Chief of Hepatology
  • Professor of Medicine
  • University of California San Diego
  • San Diego, California
    • Adrian M. Di Bisceglie, MD, FACP, and Robert G. Gish, MD, co-chair this free, long-form CME/CE program featuring the very latest information on screening and current and emerging treatment strategies for HBV management. Get clarity and guidance from prominent hepatology experts on key issues and practice challenges. Earn CME/CE credit and complete all courses to earn your Certificate of Advanced Study.

  • Analyze the serious disease burden of HBV infection, risk factors, and the need for early screening and diagnosis of at-risk patients to initiate further steps that improve patient outcomes.
  • Evaluate the impact of cultural/language differences and barriers in screening, diagnosing, and treating chronic HBV infection in high-risk populations among Asian and Pacific-Islanders, Latinos, blacks, and white communities to bridge these differences, and facilitate screening, diagnosis, and treatment that improves patient outcomes.
  • Assess clinical relevance of HBV tests in determining when to treat, optimal treatment selection in chronic HBV-infected patients with diverse ethnic backgrounds, and in evaluating on-treatment response to therapy to improve patient outcomes.
  • Translate treatment guidelines into practical recommendations for the practice setting, to optimize screening, diagnosis, and treatment of patients with chronic HBV infection.
  • Analyze thresholds for which patients you treat and how, and which patients you follow, to improve outcomes.
  • Formulate anti-HBV treatment strategies, considering efficacy, therapeutic endpoints, safety, and resistance profiles of currently available and emerging antiviral agents, to minimize the development of resistance and monitor response for treatment adjustments to improve response rates in patients with chronic HBV infection.
  • Implement optimal treatment selection for special populations with HBV infection, including immigrants, pregnant women, patients with coinfections, and transplant patients, to improve outcomes.
  • Analyze how HBV infection leads to the development of HCC and/or cirrhosis in order to implement strategies for the prevention and treatment of HBV and HCC.

    • Target Audience

    This CME/CE activity is designed for gastroenterologists, hepatologists, infectious disease specialists, internal medicine and primary care providers, nurse practitioners, nurses, physician assistants, and pharmacists who specialize in and care for patients with HBV.

     

    Activity Goal

    The goal of this CME/CE activity is to increase clinicians’ awareness of HBV disease prevalence, prevention strategies, and screening and diagnostic methodology within the high-risk HBV patient populations; bridge cultural differences in communicating diagnosis and treatment; provide current and emerging strategies for the selection of patients for treatment; educate clinicians on current treatment options; and expand on treatment management skills for HBV-infected patients.